# Bitopertin

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/bitopertin
Canonical HTML page: https://gethealthbrief.com/entity/bitopertin

## Timeline

- **2026-Q4**: APOLLO Data Readout — Expected release of Phase 2 data which will support the traditional NDA filing.
- **2026-02-23**: FDA CRL Issued — Disc Medicine receives a Complete Response Letter for bitopertin's accelerated approval application.
- **2026-02-23**: Strategic Pivot — Company announces shift to traditional approval pathway for EPP indication.

## Recent coverage (1 stories)

### Disc Medicine Pivots to Traditional FDA Path for Bitopertin Following CRL
2026-02-23 22:44:21 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Disc Medicine is shifting its regulatory strategy for bitopertin in erythropoietic protoporphyria (EPP) after receiving a Complete Response Letter from the FDA. The company will now pursue a traditional approval pathway, with critical Phase 2 APOLLO trial data expected in the fourth quarter of 2026.
Full story: https://gethealthbrief.com/story/disc-medicine-bitopertin-fda-crl-apollo-data

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.